Deals
Sanofi Said to Weigh Sale of Some Anti-Inflammatory Products
- Mature inflammation assets could fetch up to 200 million euros
- French drugmaker is focusing on innovative new therapies
This article is for subscribers only.
Sanofi is weighing a sale of some of its older anti-inflammatory products, according to people familiar with the matter, as it swivels toward innovative new therapies.
The French drugmaker is studying options for the assets, the people said, asking not to be identified because the information is private. The assets include several mature inflammation treatments and could fetch as much as 200 million euros ($234 million), according to the people.